Mindpeak secures $15.3M in series A funding to accelerate growth in AI-based digital pathology

Mindpeak has been granted its first patent, marking an important milestone in the company’s mission to advance AI-powered pathology and precision diagnostics.

The patent protects a novel method for training artificial intelligence systems to accurately identify and classify different cell types in tissue samples. This technology addresses a critical requirement for reliable cancer diagnostics and reinforces the role of AI as a dependable decision-support tool for pathologists.

The patent has been issued across 18 European Union member states and validated in the United Kingdom, highlighting the originality, robustness, and clinical relevance of Mindpeak’s approach to digital pathology.

This achievement reflects the dedication and expertise of Mindpeak’s research, development, and engineering teams, whose work continues to advance the capabilities of medical AI.

For further information, please refer to the full press release:
https://www.globenewswire.com/news-release/2025/12/10/3202933/0/en/Mindpeak-Secures-First-Patent-for-Advanced-AI-Method-in-Digital-Pathology.html

‍

The role of AI in pathology isn’t just evolving – it’s accelerating. It’s helping pathologists turn complex data into faster, more consistent answers for patients. At Mindpeak, we’re proud to be part of that change. Today, we’re taking another big step forward through a new collaboration with PathGroup – one of the leading providers of anatomic, clinical, molecular and digital pathology services in the U.S.

This partnership goes beyond collaboration; it marks a powerful step toward bringing AI into everyday diagnostics. By combining Mindpeak’s proprietary image analysis technology with PathGroup’s extensive, pathologist-led network, we’re laying the groundwork for a new era of precision and efficiency in pathology.

Together, we’ll support pathologists integrate AI seamlessly into their workflows – enhancing speed, consistency and equity in diagnostics. The result: faster, more reliable insights for patients and more time for pathologists to focus on what matters most – patient care.

At Mindpeak, we believe the future of pathology is AI-augmented, not AI-replaced. Through partnerships like this, that future is becoming reality – one slide at a time.

‍

‍

Read more here

We’re proud to introduce PhenoScout AI, our next-generation multiplex immunofluorescence (mIF) analysis solution.

By automating phenotype identification, biomarker quantification, and spatial readouts, PhenoScout AI reduces variability and supports large-scale studies. The solution is designed for pharma, diagnostics, and academic research to accelerate translational medicine.

👉 Learn more

‍